Kidney-targeted drug delivery systems

A pharmaceutical composition, comprising:

• a therapeutically effective amount of elastin-like polypeptide (ELP) coupled to a therapeutic agent, the ELP including an amino acid sequence having between 5 and 320 repeats of the amino acid sequence GVPGX (SEQ ID NO:
• 1), wherein X in the sequence GVPGX (SEQ ID NO:
• 1) is any amino acid except proline;
• a pharmaceutically acceptable carrier;
• and
• a kidney targeting agent coupled to the ELP, wherein the kidney targeting agent comprises an amino acid sequence of SEQ ID NO:
• 5;
• wherein the therapeutically effective amount of the ELP coupled to the therapeutic agent improves the deposition and retention of the therapeutic agent mostly in the renal cortex relative to a non-conjugated therapeutic, and wherein the pharmaceutical composition enhances the deposition and retention of the therapeutic agent in the kidney relative to the non-conjugated therapeutic.

A pharmaceutical composition, comprising:

• a therapeutically effective amount of elastin-like polypeptide (ELP) coupled to a therapeutic agent, the ELP including an amino acid sequence having between 5 and 320 repeats of the amino acid sequence GVPGX (SEQ ID NO:
• 1), wherein X in each repeat of the sequence GVPGX (SEQ ID NO:
• 1) is any amino acid except proline, and wherein the ELP comprises the amino acid sequence of SEQ ID NO:
• 2, 3, or 4;
• a pharmaceutically acceptable carrier;
• and
• a kidney targeting agent coupled to the ELP, wherein the kidney targeting agent comprises an amino acid sequence of SEQ ID NO:
• 5;
• wherein the therapeutically effective amount of the ELP coupled to the therapeutic agent improves the deposition and retention of the therapeutic agent mostly in the renal cortex relative to a non-conjugated therapeutic, and wherein the pharmaceutical composition enhances the deposition and retention of the therapeutic agent in the kidney relative to the non-conjugated therapeutic.

A pharmaceutical composition, comprising:

• a therapeutically effective amount of elastin-like polypeptide (ELP) coupled to a therapeutic agent, the ELP including an amino acid sequence having between 5 and 320 repeats of the amino acid sequence GVPGX (SEQ ID NO:
• 1), wherein X in each repeat of the sequence GVPGX (SEQ ID NO:
• 1) is any amino acid except proline;
• a pharmaceutically acceptable carrier;
• a kidney targeting agent coupled to the ELP, wherein the kidney targeting agent comprises an amino acid sequence of SEQ ID NO:
• 5;
• and
• a drug binding domain coupled to the ELP, wherein the drug binding domain is configured to bind to the therapeutic agent and comprises the amino acid sequence of SEQ ID NO:
• 9, 10, 11, 12, or combination thereof, and
• wherein the therapeutically effective amount of the ELP coupled to the therapeutic agent improves the deposition and retention of the therapeutic agent mostly in the renal cortex relative to a non-conjugated therapeutic, and wherein the pharmaceutical composition enhances the deposition and retention of the therapeutic agent in the kidney relative to the non-conjugated therapeutic.